Significant Financial Performance in Q3 2025
Photocure ASA (OSE: PHO) recently announced a robust financial performance for the third quarter of 2025. The company reported Hexvix/Cysview revenues reaching NOK 134.1 million, representing an increase from NOK 120.1 million during the same quarter last year. In addition, Photocure achieved an EBITDA of NOK 10.2 million compared to NOK 5.0 million in Q3 2024, underlining the company's momentum in the bladder cancer diagnostics space.
Continued Product Revenue Growth
Positive Outlook for Future Performance
Looking forward, Photocure is optimistic about sustaining product revenue growth, projecting an increase of 8% to 10% on a constant currency basis. This forecast refines the previous guidance of 7% to 11%, indicating the company's steady progress and increased sales efficiency driven by operating leverage in their commercial ventures.
Executive Insights
“Photocure delivered another strong quarter, extending our track record of double-digit topline revenue growth with positive EBITDA. We continued to execute with discipline this quarter while advancing new growth initiatives that amplify our central role in precision diagnostics for bladder cancer,” said Dan Schneider, President and CEO of Photocure. His comments reflect the company's commitment to excellence and innovation in the healthcare industry.
Expansion of Blue Light Cystoscopy Use
Investing in Innovative Technologies
As part of its growth strategy, Photocure advanced the installation of blue light cystoscopy (BLC) systems, adding 14 new Saphira towers in the U.S. This included seven new accounts and seven upgrades to existing towers, reflecting a proactive approach to meet increasing demand. The partnership with ForTec resulted in an additional six mobile BLC towers being deployed, bringing the total to 24 and enhancing access for clinicians in their cancer detection efforts. With these efforts combined, Photocure ended the quarter with 373 active accounts in the U.S., a marked increase of 23% from the previous quarter.
Partnerships and Innovations
Collaboration with Intelligent Scopes Corporation
After the quarter closed, Photocure announced an exciting partnership with Intelligent Scopes Corporation (ISC), focused on developing AI software to assist physicians in real-time during bladder cancer treatments. This innovation aims to enhance early detection and diagnosis, ultimately improving patient outcomes. Photocure will retain exclusive rights to commercialize this software, indicating its strategic foresight in aligning technology with healthcare demands.
Looking Ahead: Revenue Growth Potential
Strategic Expansion Plans
Photocure's leadership remains enthusiastic about future revenue growth, which is anticipated to be driven by increased adoption of their technologies, the expansion of the mobile BLC systems, and upgrades that leverage high-definition capabilities to improve utilization rates. Schneider noted several catalysts that could further support their growth trajectory, including favorable reimbursement developments and potential FDA reclassification for broadened patient access to the BLC systems.
Exciting Developments on the Horizon
In addition to these operational advancements, ongoing licensing agreements, especially with Asieris for Cevira, could lead to significant milestone payments upon successful regulatory approval in China. This potential underscores Photocure's dedication to driving innovation within the bladder cancer management landscape.
Final Financial Overview and Additional Information
In summary, for Q3 2025, total revenues stood at NOK 135.0 million, an increase from NOK 120.2 million, accompanied by an EBIT of NOK 2.9 million. The financial strength is complemented by cash reserves of NOK 247.8 million at the quarter's end, providing a solid foundation for future initiatives.
Frequently Asked Questions
What were Photocure's revenues for Q3 2025?
Photocure reported revenues of NOK 135.0 million for the third quarter of 2025.
What is the forecast for Photocure's revenue growth?
Photocure forecasts a product revenue growth of 8% to 10% for the upcoming year.
What new technologies is Photocure implementing?
Photocure is enhancing its blue light cystoscopy systems, with the installation of new Saphira towers and partnerships to develop AI software for real-time assistance during treatments.
Who is the CEO of Photocure ASA?
Dan Schneider is the President and CEO of Photocure ASA.
Where can I find more information about Photocure?
For further information, you can contact Dan Schneider, the President and CEO via the provided emails.
